Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03953300 · ClinicalTrials.gov registry record · Phase 4
Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics
A Phase 4 study of Asthma, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 4
- Development phase
- 75
- Enrollment target
- 20
- Study locations
NCT03953300 is a Phase 4 study of Asthma that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 75 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (95% lower). The trial reports 20 study locations across 15 states.
The verdict
NCT03953300, a Phase 4 study of Asthma, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 75 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to evaluate effect of benralizumab on structural and lung function changes in severe eosinophilic asthmatics. Changes will be assessed over 48 week treatment period in patients with persistent symptoms despite standard therapy of inhaled corticosteroids (ICS) plus long acting B2-agonist (LABA) with or without additional controller medication. Patients who complete treatment will enter 4 weeks follow-up period.
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Benralizumab
Study Locations (20)
Texas
- Research Site - Galveston
- Research Site - Lewisville
- Research Site - Mansfield
Florida
- Research Site - Jacksonville
- Research Site - Miami
Michigan
- Research Site - Ann Arbor
- Research Site - Bloomfield Hills
North Carolina
- Research Site - New Bern
- Research Site - Winston-Salem
Alabama
- Research Site - Birmingham
California
- Research Site - Los Angeles
Georgia
- Research Site - Snellville
Indiana
- Research Site - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2019-10-08 |
| Est. Completion | 2026-10-19 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03953300
The ClinicalTrials.gov registry entry for NCT03953300 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (95% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03953300 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Texas, Florida, Michigan.
Frequently Asked Questions
What is clinical trial NCT03953300 about?
NCT03953300 is a clinical study titled "Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics". The purpose of the study is to evaluate effect of benralizumab on structural and lung function changes in severe eosinophilic asthmatics. Changes will be assessed over 48 week treatment period in patients with persistent symptoms despite standard therapy of inhaled corticosteroids (ICS) plus long a...
What is the current status of trial NCT03953300?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 75 participants. The study started on 2019-10-08. Estimated completion is 2026-10-19.
What conditions does trial NCT03953300 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT03953300?
The interventions under investigation include: Placebo (BIOLOGICAL), Benralizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT03953300?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03953300 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Georgia, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma
RECRUITING · Phase 4
-
Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma
RECRUITING · Phase 4
-
Viral Infection in Asthma (VIA) Study
RECRUITING · Phase 4
-
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
RECRUITING · Phase 4
-
The Effects of Positive Airway Pressure on the Mucolytic Effects of NAC (TEAM)
RECRUITING · Phase 4
-
Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.